Take the chance to join an Astellas Pharma sponsored webinar with Dr. Mark J. Levis, MD, PhD, Baltimore, USA, entitled Ask the expert: FLT3 MRD testing in AML patients via Teams with the following agenda:
Assess the current minimal residual disease testing modalities/methods
Evaluate appropriate timing and efficacy of different FLT3 MRD testing modalities
Summarize the appropriate treatment strategies in a post-transplant setting
Best practice sharing in developing/setting up FLT3 MRD testing
